MedTrace Logo

PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma

NCT01304485 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2000

Last updated 2019-03-07

No results posted yet for this study

Summary

Positron emission tomography (PET) imaging evaluation in men with recurrent prostate cancer to select patients who may benefit from directed therapy

Conditions

Interventions

DRUG

Sodium Acetate C11

PET Imaging with Sodium Acetate C11

Sponsors & Collaborators

  • Phoenix Molecular Imaging

    lead OTHER

Principal Investigators

  • Fabio Almeida, M.D. · Medical Director, Phoenix Molecular Imaging

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2019-01-31
Completion
2019-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01304485 on ClinicalTrials.gov